Publications by authors named "Shinsuke Shiotsu"

Claim this Profile
C
Clinical impact of cancer cachexia on the outcome of patients with non-small cell lung cancer with PD-L1 tumor proportion scores of ≥50% receiving pembrolizumab monotherapy versus immune checkpoint inhibitor with chemotherapy.
Hayato Kawachi, Tadaaki Yamada, Motohiro Tamiya, Yoshiki Negi, Takashi Kijima, Shinsuke Shiotsu

Oncoimmunology· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic factors in patients with interstitial lung disease treated with nintedanib: a multicenter retrospective study in Japan.
Shiho Goda, Tadaaki Yamada, Yasuhiro Goto, Sayaka Uda, Akira Nakao, Shinsuke Shiotsu

Sci Rep· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Chemoimmunotherapy in Patients With Advanced Non-small Cell Lung Cancer With Pre-existing Interstitial Pneumonia and Low PD-L1 Expression.
Aosa Sasada, Hayato Kawachi, Tadaaki Yamada, Tae Hata, Yasuhiro Goto, Shinsuke Shiotsu

Anticancer Res· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selecting optimal immunotherapy based on inflammation in stage IV PD-L1 ≥50% gene mutation-negative non-small cell lung cancer: pembrolizumab monotherapy versus combination chemoimmunotherapy.
Yusuke Kunimatsu, Naoya Nishioka, Tadaaki Yamada, Hayato Kawachi, Motohiro Tamiya, Shinsuke Shiotsu

Transl Lung Cancer Res· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemoimmunotherapy Outcomes and Prognostic Factors in Patients with Advanced, Low PD-L1-Expressing Non-Small Cell Lung Cancer.
Tae Hata, Tadaaki Yamada, Yasuhiro Goto, Akihiko Amano, Yoshiki Negi, Shinsuke Shiotsu

Cancer Res Commun· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Randomized Trial of Nutrition and Exercise Treatment in Patients With Pancreatic and Non-Small Cell Lung Cancer (NEXTAC-TWO).
Shuichi Mitsunaga, Tateaki Naito, Hisao Imai, Madoka Kimura, Satoru Miura, Shinsuke Shiotsu

J Cachexia Sarcopenia Muscle· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of mutant protein expression on clinical outcomes in patients with EGFR L858R-mutated non-small cell lung cancer.
Ryota Nakamura, Tadaaki Yamada, Kenji Morimoto, Akihiro Yoshimura, Shinsuke Shiotsu

Transl Lung Cancer Res· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regimen Selection for Chemoimmunotherapy in Nonsquamous Non-Small Cell Lung Cancer with Low PD-L1 Expression: A Multicenter Retrospective Cohort Study.
Tae Hata, Tadaaki Yamada, Yasuhiro Goto, Akihiko Amano, Yoshiki Negi, Shinsuke Shiotsu

Clin Lung Cancer· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of chemotherapy with or without immunotherapy in older patients with non-small cell lung cancer and low PD-L1 expression.
Hayato Kawachi, Tae Hata, Tadaaki Yamada, Yasuhiro Goto, Akihiko Amano, Shinsuke Shiotsu

Transl Lung Cancer Res· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of TTF-1 Expression on the Prognostic Prediction of Patients with Non-Small Cell Lung Cancer with PD-L1 Expression Levels of 1% to 49%, Treated with Chemotherapy vs. Chemoimmunotherapy: A Multicenter, Retrospective Study.
Naoya Nishioka, Tae Hata, Tadaaki Yamada, Yasuhiro Goto, Akihiko Amano, Shinsuke Shiotsu

Cancer Res Treat· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of immune-related adverse events on clinical outcomes in patients with advanced non-small cell lung cancer with low PD-L1 expression, focusing on pneumonitis: a multicenter retrospective study in Japan.
Shiho Goda, Tadaaki Yamada, Kenji Morimoto, Tae Hata, Yasuhiro Goto, Shinsuke Shiotsu

Transl Lung Cancer Res· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative analysis of first-line treatment in NSCLC including unresectable stage III (IIIB/IIIC) and stage IV with low PD-L1 expression: Clinical trial eligible versus ineligible patients.
Tae Hata, Tadaaki Yamada, Yasuhiro Goto, Akihiko Amano, Yoshiki Negi, Shinsuke Shiotsu

Lung Cancer· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mediastinal Lymphadenopathy Diagnosed as Prostate Cancer via Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration (EBUS-TBNA) in a Patient With a History of Renal Cell Carcinoma: A Case Report.
Naoaki Tsuji, Hirai Soichi, Kano Yukari, Tanimura Mai, Shiotsu Shinsuke

Cureus· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cytokine Release Syndrome with Relative Adrenal Insufficiency Induced by Ipilimumab and Nivolumab Combination Therapy for Clear Cell Renal Cell Carcinoma.
Kohei Yamamoto, Shinsuke Shiotsu, Misaki Sasakura, Shunya Tanaka, Shiho Goda

Intern Med· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Depth of response and treatment outcomes of immune checkpoint inhibitor-based therapy in patients with advanced non-small cell lung cancer and high PD-L1 expression: An exploratory analysis of retrospective multicenter cohort.
Yusuke Tachibana, Kenji Morimoto, Tadaaki Yamada, Hayato Kawachi, Motohiro Tamiya, Shinsuke Shiotsu

Invest New Drugs· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CYFRA 21-1 predicts efficacy of combined chemoimmunotherapy in patients with advanced non-small cell lung cancer: a prospective observational study.
Nobutaka Kataoka, Yuki Katayama, Tadaaki Yamada, Kenji Morimoto, Takayuki Takeda, Shinsuke Shiotsu

Transl Lung Cancer Res· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Unraveling the influence of TTF-1 expression on immunotherapy outcomes in PD-L1-high non-squamous NSCLC: a retrospective multicenter study.
Naoya Nishioka, Hayato Kawachi, Tadaaki Yamada, Motohiro Tamiya, Yoshiki Negi, Shinsuke Shiotsu

Front Immunol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prospective Observational Study of Ramucirumab Plus Docetaxel After Combined Chemoimmunotherapy in Patients With Non-Small-Cell Lung Cancer.
Yuki Katayama, Tadaaki Yamada, Ryo Sawada, Hayato Kawachi, Kenji Morimoto, Shinsuke Shiotsu

Oncologist· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Docetaxel plus Ramucirumab for Patients with Pretreated Advanced or Recurrent Non-small Cell Lung Cancer: Focus on Older Patients.
Keisuke Onoi, Tadaaki Yamada, Kenji Morimoto, Hayato Kawachi, Rei Tsutsumi, Shinsuke Shiotsu

Target Oncol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AXL signal mediates adaptive resistance to KRAS G12C inhibitors in KRAS G12C-mutant tumor cells.
Kenji Morimoto, Tadaaki Yamada, Soichi Hirai, Yuki Katayama, Sarina Fukui, Shinsuke Shiotsu

Cancer Lett· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparing Three Different Anti-Programmed Death-Ligand 1 Antibodies in Immunohistochemical Evaluation of Combined Chemoimmunotherapy Response in Patients With NSCLC: A Prospective Study.
Yuki Katayama, Tadaaki Yamada, Kenji Morimoto, Hiroyuki Fujii, Satomi Morita, Shinsuke Shiotsu

JTO Clin Res Rep· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic impact of clinical factors for immune checkpoint inhibitor with or without chemotherapy in older patients with non-small cell lung cancer and PD-L1 TPS ≥ 50.
Shota Takei, Hayato Kawachi, Tadaaki Yamada, Motohiro Tamiya, Yoshiki Negi, Shinsuke Shiotsu

Front Immunol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of the response to platinum-based chemotherapy on the second-line immune checkpoint inhibitor monotherapy in non-small cell lung cancer with PD-L1 expression ≤49%: a multicenter retrospective study.
Akihiro Yoshimura, Takayuki Takeda, Nobutaka Kataoka, Keiko Tanimura, Mototaka Fukui, Shinsuke Shiotsu

Front Oncol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemoimmunotherapy Versus Pembrolizumab as a First-Line Treatment for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression: Focus on the Role of Performance Status.
Kenji Morimoto, Tadaaki Yamada, Hayato Kawachi, Motohiro Tamiya, Yoshiki Negi, Shinsuke Shiotsu

Target Oncol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-Line Chemoimmunotherapy versus Sequential Platinum-Based Chemotherapy Followed by Immunotherapy in Patients with Non-Small Cell Lung Cancer with ≤49% Programmed Death-Ligand 1 Expression: A Real-World Multicenter Retrospective Study.
Keiko Tanimura, Takayuki Takeda, Nobutaka Kataoka, Akihiro Yoshimura, Kentaro Nakanishi, Shinsuke Shiotsu

Cancers (Basel)· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis